Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-3083.2011.03978.xPMID 21348897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• The biology behind prognostic factors of cutaneous melanoma

  2010cited by this paper
• Biomarkers in melanoma

  2009cited by this paper
• Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.

  2009cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

  2009cited by this paper
• Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix

  2009cited by this paper
• Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients.

  2009cited by this paper
• Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor-specific antigenic peptides.

  2009cited by this paper
• Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients

  2009cited by this paper
• Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

  2008cited by this paper
• A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

  2008cited by this paper
• Downregulation of CCN3 expression as a potential mechanism for melanoma progression

  2008cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Role of ING4 in human melanoma cell migration, invasion and patient survival.

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients

  2007cited by this paper
• Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.

  2007cited by this paper
• Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.

  2007cited by this paper
• Involvement of E‐cadherin, β‐catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma

  2007cited by this paper
• Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

  2007cited by this paper
• Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells

  2007cited by this paper
• Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma

  2007cited by this paper
• Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9.

  2006cited by this paper
• Prognostic Significance of Extent of Ulceration in Primary Cutaneous Melanoma

  2006cited by this paper
• Gene expression profiling of primary cutaneous melanoma and clinical outcome.

  2006cited by this paper
• Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma

  2006cited by this paper
• A population-based validation of the American Joint Committee on Cancer melanoma staging system.

  2005cited by this paper
• Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

  2005cited by this paper
• Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium.

  2005cited by this paper
• Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.

  2004cited by this paper
• NF-κB in the Vascular Progression of Melanoma

  2004cited by this paper
• The Prognostic Importance of Tumor Mitotic Rate Confirmed in 1317 Patients With Primary Cutaneous Melanoma and Long Follow-Up

  2004cited by this paper
• NF-kappa B in the vascular progression of melanoma.

  2004cited by this paper
• Is parathyroid carcinoma a lethal disease

  2004cited by this paper
• Mitotic Rate as a Predictor of Sentinel Lymph NodePositivity in Patients With Thin Melanomas

  2004cited by this paper
• Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma

  2003cited by this paper
• The Role of Altered Cell–Cell Communication in Melanoma Progression

  2003cited by this paper
• Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas.

  2003cited by this paper
• Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

  2002cited by this paper
• Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplati

  2002cited by this paper
• Prognostic factors in patients with thick cutaneous melanoma (> 4 mm)

  2002cited by this paper
• Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

  2002cited by this paper
• Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin

  2002cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

  2001cited by this paper
• High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement

  2001cited by this paper
• Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?

  1999cited by this paper
• Expression of c‐myc oncoprotein represents a new prognostic marker in cutaneous melanoma

  1998cited by this paper
• A long-term analysis of 620 patients with malignant melanoma at a major referral center.

  1998cited by this paper
• Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.

  1995cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• Continuous interleukin‐2 and tumor‐infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

  1991cited by this paper
• The prognostic significance of ulceration of cutaneous melanoma

  1980cited by this paper

• Nursing Management of Cutaneous Toxicities From Epidermal Growth Factor Receptor Inhibitors.

  2016cites this paper
• Eradication of established murine mesothelioma tumours by combined immunotherapy

  2015cites this paper